Clinitech Laboratory
42.00
-42.00(-100.00%)
Market Cap₹9.60 Cr
PE Ratio24.28
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Clinitech Laboratory
20Mar 26
Clinitech Laboratory Promoter Increases Stake with 4,800 Share Acquisition
Jagdish Umakant Nayak, promoter and managing director of Clinitech Laboratory Limited, has acquired 4,800 additional equity shares through open market transactions on March 19-20, 2026. This acquisition increased the promoter group's shareholding from 63.78% to 63.99%, representing a 0.21% increase in their stake in the BSE-listed company.
 no imag found
14Mar 26
Clinitech Laboratory Promoter Continues Stake Building with 6,000 Share Purchase
Clinitech Laboratory Limited's promoter and Managing Director Jagdish Umakant Nayak has disclosed the acquisition of 6,000 equity shares through open market transactions conducted over March 12-13, 2026. This latest purchase increases his shareholding from 30.92% to 31.18% of the company's total voting capital of 22,82,400 shares, representing a cumulative increase of 0.79% across recent acquisitions.
 no imag found
17Feb 26
Clinitech Laboratory Limited Incorporates Analog IVD Solutions as Medical Products Subsidiary
Clinitech Laboratory Limited has incorporated Analog IVD Solutions Private Limited as a subsidiary with 60% shareholding, authorized capital of INR 10 lakhs, and subscribed capital of INR 1 lakh. The new company will focus on trade and manufacturing of medical/pathological products, receiving its incorporation certificate on February 17, 2026, following proper regulatory compliance under SEBI (LODR) Regulations, 2015.
 no imag found
06Feb 26
Clinitech Laboratory Limited Board Approves Subsidiary Formation and INR 22.50 Lakhs Term Loan
Clinitech Laboratory Limited's board meeting on February 06, 2026, resulted in two strategic approvals: formation of Analog IVD Solutions Private Limited subsidiary and securing a term loan of INR 22.50 lakhs from Bank of Baroda. The 20-minute meeting at the registered office demonstrates the company's focus on expansion and financial strengthening. These decisions reflect the company's commitment to diversification and operational enhancement in the diagnostic solutions sector.
 no imag found
27Jan 26
Clinitech Laboratory Limited Board Approves Subsidiary Formation and ICC Reconstitution
Clinitech Laboratory Limited's board meeting on January 27, 2026, resulted in approval of subsidiary company formation and reconstitution of the Internal Complaint Committee with revised POSH policy. The 30-minute meeting demonstrated efficient governance while addressing both strategic expansion and workplace safety compliance requirements.
 no imag found
19Dec 25
Clinitech Laboratory Limited Receives Incorporation Certificate for Healthcare Subsidiary
Clinitech Laboratory Limited has successfully incorporated its healthcare subsidiary Medicarenx Multispeciality Hospital Private Limited, receiving the Certificate of Incorporation from MCA on December 19, 2025. The subsidiary has an authorized share capital of ₹50 lakhs with Clinitech holding 60% ownership through 6,000 equity shares, marking the company's strategic expansion into multispeciality hospital services.
 no imag found
17Nov 25
Clinitech Laboratory Expands Diagnostic Services through Partnership with MDM Dawudi Hospital
Clinitech Laboratory Limited has announced a strategic collaboration with MDM Dawudi Hospital Pvt Ltd to establish a new diagnostic centre named 'CTL Dombivli' in the Dombivli region. The partnership, formalized through an MOU, aims to jointly develop, manage, and expand pathology and radiology services. This move is expected to enhance Clinitech's market presence and diversify its service offerings in the diagnostic services sector.
 no imag found
12Nov 25
Clinitech Laboratory Reports Mixed H1 FY2026 Results, Approves Subsidiary Formation
Clinitech Laboratory Limited announced unaudited financial results for H1 FY2026. Revenue grew 24.64% YoY to ₹508.02 lakhs, but profit after tax declined 27.25% QoQ to ₹21.41 lakhs. The company approved formation of a new subsidiary and has utilized ₹428.30 lakhs of its ₹578.30 lakhs IPO proceeds, with ₹150 lakhs remaining for diagnostic business expansion.
 no imag found
05Aug 25
Clinitech Laboratory Limited Enhances Services with New In-House Molecular Testing Department
Clinitech Laboratory Limited has announced the introduction of an in-house molecular department for all tests, enhancing its medical services. This strategic move aims to improve diagnostic capabilities, potentially offering faster turnaround times, better quality control, and a more comprehensive service offering for patients. The expansion aligns with industry trends towards integrated and advanced diagnostic services, potentially strengthening Clinitech's market position.
 no imag found
Clinitech Laboratory
42.00
-42.00
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
Dr. Lal Path Labs
1,415.50
(-1.08%)
Vijaya Diagnostic Centre
1,030.85
(+0.13%)
Metropolis Healthcare
468.80
(-0.72%)
Krsnaa Diagnostics
603.75
(-1.26%)
Suraksha Diagnostic
283.00
(+0.83%)
3B BlackBio DX
1,293.90
(+0.16%)
Sastasundar Ventures
270.45
(+0.45%)